ORPHA:96253
Cushing disease
Also known as: Corticotroph pituitary adenoma · Pituitary corticotroph micro-adenoma · Pituitary-dependent Cushing syndrome
Publications
9,944
93.7th percentile
Trials
39
Interventional, condition-specific
Researchers
1,086
Distinct authors in sample
Gene link
—
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A form of adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome, an endogenous Cushing syndrome (CS), characterized by chronic over-secretion of adrenocorticotropic hormone (ACTH) due to a pituitary corticotroph adenoma.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009050
- MeSH:D049913
- OMIM:219090
- UMLS:C0221406
- NCIT:C113210
Additional Mondo synonyms (11)
ACTH producing pituitary adenoma · Cushing disease, pituitary · Cushing's disease · PITA4 · corticotroph pituitary adenoma · pituitary adenoma 4, ACTH-secreting · pituitary adenoma 4, ACTH-secreting, somatic · pituitary adenoma, ACTH-secreting · pituitary corticotroph micro-adenoma · pituitary dependent Cushing syndrome · pituitary-dependent Cushing syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
9,944 matched papers (3,948 in last 10 years) Source
- Phenotype characterisedPresent
92 HPO annotations (e.g. Truncal obesity; Immunodeficiency; Increased circulating ACTH level) Source
- Animal modelPresent
2 genotype models (Mus musculus) Source
- Orphan designationPartial
2 FDA · 1 EMA designations (none yet with FDA orphan-indication approval) — e.g. osilodrostat Source
- Interventional trialPresent
39 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
92
Associated phenotypes · MONDO:0009050
- Truncal obesity
- Immunodeficiency
- Increased circulating ACTH level
- Proximal amyotrophy
- Moon facies
Showing 5 of 92 — open Monarch for the full list.
Animal models (Monarch / Alliance)
2
Model associations linked to this Mondo ID
- Tg(PyLT)1Vb/0 [background:] Not Specified·MGI:5805519·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
3
Designations · no FDA orphan-indication approval yet
- FDA osilodrostat (Isturisa)Cushing's disease · 2013-09-13
- FDA pasireotide (Signifor)Cushing's disease · 2009-07-24
- EMA pasireotideTreatment of Cushing's disease · 08/10/2009 · ExpiredEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
9,944
9,944 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
9,944 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,948 in the last 10 years · medium confidence · 93.7th percentile (publications denominator)
Phrase hits: 9,936 · MeSH hits: 17
Who's working on it?
1,086
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Fleseriu M8 papers · 2026
Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, United States.
Papers in Europe PMC - 02Agrawal N6 papers · 2026
Department of Endocrinology, NYU School of Medicine, New York 10016, United States.
Papers in Europe PMC - 03Feelders RA6 papers · 2026
Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; Holman Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University Langone Medical Center, New York, USA. Electronic address: R.Feelders@erasmusmc.nl.
Papers in Europe PMC - 04Zhang Y6 papers · 2026
Department of Neurosurgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China.
Papers in Europe PMC - 05Akirov A5 papers · 2026
Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
Papers in Europe PMC - 06Honegger J5 papers · 2026
Department of Neurosurgery, University Hospital Tuebingen, Eberhard-Karls-University Tuebingen, Germany.
Papers in Europe PMC - 07Kushnir S5 papers · 2026
Research Authority, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel.
Papers in Europe PMC - 08Newell-Price J5 papers · 2026
The School of Medicine and Population Health, University of Sheffield, Sheffield, S10 2RX, United Kingdom.
Papers in Europe PMC - 09Rudman Y5 papers · 2026
Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel.
Papers in Europe PMC - 10Shochat T5 papers · 2026
Biostatistics Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
39
interventional trials for this specific condition
39 interventional trials matched this specific condition name; 8 currently recruiting in our sample.
Data as of 11 September 2026
39 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.7th percentile).
medium confidence · 96.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
39 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05971758·RECRUITING·Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Not reviewed·Conditions: Cushing Disease·Matched via name phrase
- NCT05804669·RECRUITING·A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Not reviewed·Conditions: Cushing Syndrome · Cushing Disease · Ectopic ACTH Syndrome·Matched via name phrase
- NCT07603466·ENROLLING BY INVITATION·Combination Osilodrostat and Cabergoline in Cushing's Disease
Not reviewed·Conditions: Cushing Disease Due to Increased ACTH Secretion·Matched via name phrase
- NCT04569591·RECRUITING·DDAVP for Pituitary Adenoma
Not reviewed·Conditions: Cushing's Disease · Pituitary Adenoma·Matched via name phrase
- NCT03774446·RECRUITING·Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
Not reviewed·Conditions: Cushing Disease·Matched via name phrase
- NCT07108244·ENROLLING BY INVITATION·Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
Not reviewed·Conditions: Cushing Disease·Matched via name phrase
- NCT07460232·RECRUITING·FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
Not reviewed·Conditions: Cushing Disease · Pituitary Adenoma·Matched via name phrase
- NCT06471829·RECRUITING·A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Not reviewed·Conditions: Cushing's Disease·Matched via name phrase
Observational and natural-history studies
16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07335315·RECRUITING·Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors
Not reviewed·Conditions: Pituitary Adenoma · Cushing Disease·Matched via name phrase
- NCT03831958·RECRUITING·Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Not reviewed·Conditions: Cushing Disease·Matched via name phrase
- NCT07463625·RECRUITING·Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Not reviewed·Conditions: Cushing Disease · ACTH-producing Pituitary Tumour·Matched via name phrase
- NCT03364803·RECRUITING·Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not reviewed·Conditions: Cushing's Disease · Cushing Syndrome · Cushing Disease·Matched via name phrase
- NCT00001595·RECRUITING·An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Not reviewed·Conditions: Panhypopituitarism · Gigantism/Acromegaly · Prolactinoma · Cushing Disease·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 41 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- ctis·2024-514079-17-00·Expired·An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56505721·Not yet recruiting·Myoinositol in adolescent polycystic ovary syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15479264·Recruiting·A phase II trial of CY-101 in participants with adrenocortical cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47913690·Recruiting·A study looking at whether metformin (a diabetes drug) can prevent weight gain caused by antipsychotics in people experiencing their first episode of psychosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22102770·Recruiting·A study to test the safety and effects of a New Drug (LAE103) in healthy people who are overweight or obese, and in healthy postmenopausal women. The study also looks at how LAE103 works when taken alone or together with another drug (LAE102).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73588250·No longer recruiting·The purpose of the trial is to test the safety, tolerability and efficacy of the drug tildacerfont, that is being developed for the treatment of major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58111563·Recruiting·Testing oral corticosteroids versus placebo for the treatment of fibrotic hypersensitivity pneumonitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13710236·No longer recruiting·Artificial intelligence-assisted osteoporosis risk assessment in jaw x-rays
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56244307·No longer recruiting·A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49040930·No longer recruiting·A long-term study to assess the safety and efficacy of a gel treatment in subjects with Acne Vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16634513·Recruiting·Impact of a playful family education strategy with information and communication technology on childhood obesity prevention
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN47827392·No longer recruiting·Construction of the "undiseased" status bank for type 2 diabetes mellitus complicated with osteoporosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10920454·Recruiting·Measuring biomarkers using aptamers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42727091·No longer recruiting·Blocking cortisol metabolism to improve mild Cushing's syndrome due to an adrenal nodule
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36032472·No longer recruiting·Evaluation of the safety of ovarian support cell in vitro maturation (OSC-IVM) application during in vitro fertilization procedures for infertility treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62724177·No longer recruiting·A healthy volunteer study to determine the effectiveness of a needle-free test for the diagnosis of adrenal insufficiency
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73786674·No longer recruiting·Exploring the use of a digitally delivered low calorie diet and behaviour change programme on inducing diabetes remission in patients with type 2 diabetes.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76945140·No longer recruiting·Baduanjin exercise for alleviating bone pain and improving balance function in patients with primary osteoporosis: a randomized controlled trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12904794·No longer recruiting·A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31812808·No longer recruiting·Cardiac magnetic resonance shows a different heart motion in healthy obese compared to normal-weight volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74656856·No longer recruiting·A study to evaluate the efficacy and safety of Lipoxim Fire for weight management in overweight healthy women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10873942·No longer recruiting·The impact of osteoporosis on jaw bones
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32169940·No longer recruiting·A controlled study to investigate the effect of a food supplement (Femifert™) on polycystic ovarian syndrome and metabolic syndrome in women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61129760·No longer recruiting·Liraglutide and the management of overweight and obesity in people with schizophrenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83573042·No longer recruiting·Calcium supplements for the prevention of osteoporosis in perimenopausal women
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Cushing disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cushing disease" OR "Corticotroph pituitary adenoma" OR "Pituitary corticotroph micro-adenoma" OR "Pituitary-dependent Cushing syndrome" OR "ACTH producing pituitary adenoma" OR "Cushing disease, pituitary" OR "Cushing's disease" OR "PITA4" OR "pituitary adenoma 4, ACTH-secreting" OR "pituitary adenoma 4, ACTH-secreting, somatic" OR "pituitary adenoma, ACTH-secreting" OR "pituitary dependent Cushing syndrome"
MeSH descriptor terms unioned into the query: ACTH-Secreting Pituitary Adenoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cushing disease" OR "Corticotroph pituitary adenoma" OR "Pituitary corticotroph micro-adenoma" OR "Pituitary-dependent Cushing syndrome" OR "ACTH producing pituitary adenoma" OR "Cushing disease, pituitary" OR "Cushing's disease" OR "PITA4" OR "pituitary adenoma 4, ACTH-secreting" OR "pituitary adenoma 4, ACTH-secreting, somatic" OR "pituitary adenoma, ACTH-secreting" OR "pituitary dependent Cushing syndrome" OR "ACTH-Secreting Pituitary Adenoma"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 39 interventional · 16 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:00:14.855Z
